GLP-3 (Ret) is a synthetic multi-receptor incretin analogue discussed around GLP-1, GIP, and glucagon receptor pathways. It is used as a triple-agonist reference in metabolic receptor pharmacology.
Its three-pathway design supports comparative research into GLP-1, GIP, and glucagon receptor activity, including receptor selectivity, signalling, and energy-balance models.
For researchers comparing modern incretin materials, GLP-3 (Ret) is distinct from single GLP-1 analogues such as Semaglutide and dual agonists such as Tirzepatide. The specification table covers the supplied material, while batch-specific reports remain in the Test Results Library.
References
- PubMed: GLP-1, GIP, and glucagon receptor agonist research
- PubMed: triple incretin receptor agonists
Research-use notice: Supplied strictly for lawful research, laboratory, analytical, educational, or R&D purposes where permitted by applicable law. Not for human or animal use, consumption, diagnosis, treatment, food, supplement, cosmetic, veterinary, or similar end use.




